What is the generic name of Avastin?

Generic name of Avastin is Bevacizumab.

Who is the manufacturer of Avastin?

Avastin is manufactured by F. Hoffmann La Roche Ltd. and marketed by Roche Products (India) Pvt. Ltd.

Is Avastin approved by USA FDA?

Yes, Avastin is approved by FDA. The product was approved in 2009.

What is the dosage form of Avastin?

Avastin is available in 100mg/4ml and 400mg /4ml, single vial for Injection.

What are the storage conditions of Avastin?

The product should be Stored at 2° to 8°C. Avastin vials should be protected from light. Do not freeze or shake.

How Avastin is supplied?

Avastin is supplied as Single Vial for Injection of 100mg/4ml and 400mg/4ml.

How does Avastin work?

Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction of microvascular growth and inhibition of metastatic disease progression.

What is Avastin used for?

Metastatic Colorectal Cancer (mCRC)

Avastin is indicated for the first- or second-line treatment of patients with metastatic carcinoma of the colon or rectum in combination with intravenous 5-fluorouracil–based chemotherapy.

Non-Squamous Non–Small Cell Lung Cancer (NSCLC)

Avastin is indicated for the first-line treatment of unresectable, locally advanced, recurrent or metastatic non–squamous non–small cell lung cancer in combination with carboplatin and paclitaxel.

Metastatic Breast Cancer (MBC)

Avastin is indicated for the treatment of patients who have not received chemotherapy for metastatic HER2-negative breast cancer in combination with paclitaxel. The effectiveness of Avastin in MBC is based on an improvement in progression free survival. There are no data demonstrating an improvement in disease-related symptoms or increased survival with Avastin. Avastin is not indicated for patients with breast cancer that has progressed following anthracycline and taxane chemotherapy administered for metastatic disease.

Glioblastoma

Avastin is indicated for the treatment of glioblastoma with progressive disease following prior therapy as a single agent. The effectiveness of Avastin in glioblastoma is based on an improvement in objective response rate. There are no data demonstrating an improvement in disease-related symptoms or increased survival with Avastin.